Evidence map›Paper›PMID 19584277›Full record

ArticleCancer research2009

Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines.

Narasimharao V Marella, Kishore S Malyavantham, Jianmin Wang, Sei-ichi Matsui, Ping Liang, Ronald Berezney

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Narasimharao V MarellaDepartment of Biological Sciences, University at Buffalo, State University of New York, New York 14260, USA.
Kishore S Malyavantham
Jianmin Wang
Sei-ichi Matsui
Ping Liang
Ronald Berezney
University at Buffalo, State University of New York · USCancer Genetics (United States) · USRoswell Park Comprehensive Cancer Center · US

Funding

Nuclear Matrix Structure and Genomic FunctionR01GM072131 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BEREZNEY, RONALD · 2004 to 2007
$1.5M
NIGMS NIH HHS GM-072131NIGMS NIH HHS R01 GM072131
6 · The paper itself

Abstract

We used a combination of spectral karyotyping, array comparative genomic hybridization, and cDNA microarrays to gain insights into the structural and functional changes of the genome in the MCF10 human breast cancer progression model cell lines. Spectral karyotyping data showed several chromosomal aberrations and array comparative genomic hybridization analysis identified numerous genomic gains and losses that might be involved in the progression toward cancer. Analysis of the expression levels of genes located within these genomic regions revealed a lack of correlation between chromosomal gains and losses and corresponding up-regulation or down-regulation for the majority of the approximately 1,000 genes analyzed in this study. We conclude that other mechanisms of gene regulation that are not directly related to chromosomal gains and losses play a major role in breast cancer progression.

Indexed as

Gene Expression ProfilingBreastBreast NeoplasmsCell LineCell Line, TumorChromosome AberrationsComparative Genomic HybridizationCytogeneticsDisease ProgressionDown-RegulationGene Expression Regulation, NeoplasticHumansOligonucleotide Array Sequence AnalysisSpectral KaryotypingUp-Regulation

Identifiers

PMID19584277
PMCPMC2826242
OpenAlexW2117250543

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.